NetraMark Completes 2025 Annual General Meeting

Rhea-AI Summary

NetraMark Holdings Inc. (CSE: AIAI, OTCQB: AINMF), an AI solutions company focused on pharmaceutical clinical trial design, held its Annual General Meeting on June 9th, 2025. During the meeting, shareholders approved all proposed matters outlined in the May 5th Management Information Circular. The company announced the election of its board members, including PJ Haley, Dr. Joseph Geraci, George Achilleos, and Andrew Parks, with Parks being subsequently appointed as Chairman of the Board.

News Market Reaction

-3.81%

1 alert

-3.81% News Effect

On the day this news was published, AINMF declined 3.81%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) solutions company transforming clinical trial design in the pharmaceutical industry announced the successful completion of its Annual General Meeting of shareholders held on June 9th, 2025.

All matters brought before shareholders, as outlined in the Management Information Circular dated May 5, 2025, were duly approved.

The shareholders elected PJ Haley, Dr. Joseph Geraci, George Achilleos, and Andrew Parks as the directors of the Company. Following the meeting, the Board appointed Andrew Parks as Chairman.

About NetraMark
NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

Forward-Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the potential for NetraMark to transform clinical trial design in the pharmaceutical industry and the ability of its product offering to parse patient data sets and accurately segment diseases into different types and classify patients for sensitivity to drugs and/or efficacy of treatment, which are based upon NetraMark’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.

When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.ca including our Management’s Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Contact Information:
Swapan Kakumanu - CFO | swapan@netramark.com | 403-681-2549

FAQ

Who are the board members of NetraMark Holdings (AINMF) after the 2025 AGM?

The board members elected at NetraMark's 2025 AGM are PJ Haley, Dr. Joseph Geraci, George Achilleos, and Andrew Parks, with Parks serving as Chairman.

When was NetraMark Holdings (AINMF) 2025 Annual General Meeting held?

NetraMark Holdings' 2025 Annual General Meeting was held on June 9th, 2025.

Who is the Chairman of NetraMark Holdings (AINMF)?

Andrew Parks was appointed as Chairman of NetraMark Holdings following the 2025 Annual General Meeting.

What stock exchanges is NetraMark Holdings traded on?

NetraMark Holdings trades on the CSE under AIAI, OTCQB under AINMF, and Frankfurt exchange under PF0.